USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
09 Feb 2023 | 03:45 PM GMT

Business Opportunities for Digital Health in Autoimmune Conditions: Upcoming Blockbuster Drugs

Anchored by:

Erik Janssen
VP Global Digital Care Transformation
UCB PHARMA

Participants:

Erik Janssen VP Global Digital Care TransformationUCB Pharma
Erik Janssen
VP Global Digital Care TransformationUCB Pharma
Jo Peddhinti AdvisoryHLTH Community
Jo Peddhinti
AdvisoryHLTH Community
Ankit Agarwal Head of Product Strategy & InnovationBrightInsight
Ankit Agarwal
Head of Product Strategy & InnovationBrightInsight
Brian Flatley VP Consulting Services & US Pharma SolutionsS3 Connected Health
Brian Flatley
VP Consulting Services & US Pharma SolutionsS3 Connected Health
Mark Grossman VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Mark Grossman
VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Panos Papakonstantinou Global Digital Strateg. Cancer ImmunotherapyRoche Diagnostics
Panos Papakonstantinou
Global Digital Strateg. Cancer ImmunotherapyRoche Diagnostics
Reginald Swift Founder & CEORubix LS
Reginald Swift
Founder & CEORubix LS
Sarah Jackson Head of Business Development & Alliance MgmtClick Therapeutics
Sarah Jackson
Head of Business Development & Alliance MgmtClick Therapeutics
Thibault Vandenhove DirectorOoho
Thibault Vandenhove
DirectorOoho
Wen Dombrowski MD MBA Chief Convergence OfficerCATALAIZE
Wen Dombrowski MD MBA
Chief Convergence OfficerCATALAIZE

About this Meeting

Small, intimate and participant-led discussions tackling digital health challenges. Spaces are limited to 8 - 12 people, allowing you to focus on quality in-depth conversations.

Millions of people worldwide suffer from autoimmune conditions such as rheumatoid arthritis (RA), psoriasis, lupus, Crohn's disease, multiple sclerosis, atopic dermatitis, to name a few. 
While there are still a lot of challenges in patient care in autoimmune diseases, a series of promising new treatments are making their way to market. As pharma companies prepare to launch these new drugs, digital health companies have the opportunity to harness the momentum and become part of the drugs' commercialisation plans. How can they leverage this business opportunity?

Join this meeting to discuss with your peers:

  • Why is the present time an excellent opportunity for digital health in autoimmune conditions? New drugs in the market lead to a more competitive dynamic. How can pharma companies wrap their new drugs with digital health to differentiate from competitors?
  • Opportunities in the pharma value chain. Where in the pharma value chain can digital health solutions add more value (e.g. marketing, reimbursement, procurement and supply, prescription, drug use/compliance, R&D for new drug indications, etc.)? 
  • What pharma should focus on: gaps in the patient journey & impact on revenue. There are many gaps in the patient journey due to the amount of comorbidities these patients present, the lack of an integrated care, and poor adherence. Where in the patient journey can digital health solutions have the highest impact? What is in it for pharma from a revenue standpoint?
  • Challenges when incorporating digital health solutions as part of the drug launch commercialisation plan: legal and regulatory concerns, sales teams incentives, clinical evidence and building a compelling narrative to convince physicians, etc.
  • Impact on drug pricing and reimbursement. How can pharma leverage digital health solutions for higher reimbursement prices? What does a good reimbursement pricing look like, both for the pharma and digital health companies?
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.